The AI platform you buy this year will either print time or burn it. There's not much middle ground anymore. Demos still sparkle; production tells the truth. Your job as a 2025 buyer is to demand numbers that survive daylight and deadlines—benchmarks that match the way your business actually works, not how a staged task looks on a keynote slide.
Just look at the opening salvo of 2026. The FDA switched on multi-step workflow automation two days ago, moving beyond single-task bots to orchestrated agents that carry submissions through validation, risk scoring, and reporting. That's a signal. Complex, regulated work didn't crumble. It sped up, because the handoffs—once the place where projects went to die—finally held.
A week earlier, an Emirati telecom operator put AI agents into operations at live scale, handling customer flows and network events around the clock. Not a pilot. Not a sandbox. Operational—and reportedly delivering the kind of 20–30% efficiency gains you only get when the machines stop asking permission every five seconds. Telecom runs hot; if it holds there, it holds in most places.
Markets, for their part, are sobering up. Early January saw Gartner's stock slide 6.04% to roughly $237, a polite reminder that hype cycles end and ROI cycles begin. Good. Buyers are pushing for proof instead of promises. At Joe's Site, we've been nudging clients to request audit trails, orchestration logs, and real-time error budgets before signing anything with the word "autonomous." Bold? Maybe. Necessary? Definitely.